PixarBio Corporation's Dr. Jason Criscione Promoted To Chief Technology Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation today announced that Jason Criscione, PhD, has been promoted to Chief Technology Officer. Since March 2014, Dr. Criscione has led the development and translation of PixarBio's drug delivery platform. "Combining key fields of immunotherapy, drug delivery and materials science know how, Jason led the design, development, and clinical translation of our biomaterials based system for sustained, locally delivered therapeutic interventions for a multitude of neurological indications," said PixarBio CEO Frank Reynolds.

Suggested Articles

MPM and Dana-Farber have formed a venture philanthropy alliance, raising a $100 million fund and $26 million in donations to support basic research.

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.